Open an account

Dermata Therapeutics

DRMA · NASDAQ

$0.8699+$0.01 (+1.16%)TodayMarket closed ·
Prev close $0.8599

About DRMA

Dermata Therapeutics, Inc. is a clinical-stage medical dermatology company that focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin diseases. The company is headquartered in San Diego, California and currently employs 9 full-time employees. The company went IPO on 2021-08-13. The firm is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, XYNGARI and DMT410, both incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its lead product candidate, XYNGARI, is intended to utilize its Spongilla technology for once weekly treatment of a variety of skin diseases, with its initial focus being the treatment of acne vulgaris, which has a United States market size of approximately 30 million patients seeking treatment. The Company’s second product candidate, DMT410, uses its XYNGARI product candidate as a new method for needle-free intradermal delivery of botulinum toxin for the treatment of multiple aesthetic applications and medical skin diseases.

Employees
9
Headquarters
San Diego, California
Listed
Aug 13, 2021
Sector
Health Care
Industry
Biotechnology
Website
dermatarx.com

DRMA key statistics

Market cap
4.31M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
8.72M
Volume
140.08K
Open price
$0.8554
High today
$0.9275
Low today
$0.83
52 Week high
$4.66
52 Week low
$0.6032

Dermata Therapeutics (DRMA) at a glance

As of Oct 20, 2026, Dermata Therapeutics (DRMA) shares are priced at $0.8699, giving the company a market cap of 4.31M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.83 and $0.9275. The current price is 4.8% above the day's low and 6.2% below its high.

Volume so far is 140.08K shares, below the average of 8.72M shares a day.

Over the past year Dermata Therapeutics has ranged from $0.6032 to $4.66, and now sits 7% of the way up that range.

Dermata Therapeutics met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$0.74 per share against an estimate of -$0.561.

DRMA earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 16.9% on average.

  1. Q3 FY24: reported -$20.40 per share against an estimate of -$26.93
  2. Q4 FY24: reported -$20.60 per share against an estimate of -$15.30
  3. Q1 FY25: reported -$4.50 per share against an estimate of -$4.59
  4. Q2 FY25: reported -$1.66 per share against an estimate of -$2.96
  5. Q3 FY25: reported -$1.65 per share against an estimate of -$1.62
  6. Q4 FY25: reported -$1.52 per share against an estimate of -$1.57
  7. Q1 FY26: reported -$0.48 per share against an estimate of -$0.5406
  8. Q2 FY26: reported -$0.74 per share against an estimate of -$0.561

DRMA news

  • Vandana Singh

    Why Is Dermata Therapeutics Stock Gaining Thursday?

  • 12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

  • Mohd Haider

    Dermata Therapeutics Stock Surges 27% Pre-Market: Why is it Moving?

  • 12 Health Care Stocks Moving In Tuesday's After-Market Session

  • 12 Health Care Stocks Moving In Friday's Intraday Session

  • 12 Health Care Stocks Moving In Friday's Intraday Session

  • 12 Health Care Stocks Moving In Friday's Pre-Market Session

Similar companies

Companies in the same industry as Dermata Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.